Growth Metrics

Soleno Therapeutics (SLNO) EBIT (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBIT for 9 consecutive years, with $39.6 million as the latest value for Q4 2025.

  • For Q4 2025, EBIT changed N/A year-over-year to $39.6 million; the TTM value through Dec 2025 reached $9.4 million, changed N/A, while the annual FY2025 figure was $9.4 million, 105.02% up from the prior year.
  • EBIT hit $39.6 million in Q4 2025 for Soleno Therapeutics, up from $22.1 million in the prior quarter.
  • Across five years, EBIT topped out at $39.6 million in Q4 2025 and bottomed at -$45.7 million in Q1 2025.